Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.

NCT ID: NCT02892851

Last Updated: 2016-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cocaine addiction is a chronic condition with severe cardiac, neurologic, psychiatric and social complications. Cocaine is the second most consumed illicit drug in France. Its prevalence has been multiplied by 3 between 2000 and 2008, and is still on the rise. Craving, the compulsive need to consume, is a key feature of cocaine addiction. It is also predictive of treatment efficacy. However, there is no validated treatment for severe cocaine dependence yet. Response to current psychological and medical treatment is poor, with 73% relapse after 3 months. Patients with severe cocaine addiction are thus in a therapeutic deadlock.

To address these unmet medical needs, the investigators designed a pilot study (n=2) to evaluate the safety and the efficacy of the deep brain stimulation of the subthalamic nuclei (STN-DBS) in severe cocaine addiction with at least one cardiac, neurologic or psychiatric complication. Indeed, compulsivity is a critical component of craving, and severe treatment-resistant obsessive compulsive disorder (OCD) are already successfully treated using STN-DBS. Moreover, animal studies recently demonstrated a therapeutic effect of STN-DBS in rats addicted to cocaine. Together, these two lines of research suggest a therapeutic effect of STN-DBS in cocaine addiction mediated by an anti-obsessive mechanism on craving.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deep brain stimulation (DBS)

Deep brain stimulation of the subthalamic nuclei (STN-DBS)

Group Type EXPERIMENTAL

Deep brain stimulation of the subthalamic nuclei (STN-DBS)

Intervention Type DEVICE

3 phases :

* Parameter setting
* Cross-over double-bind (ON/OFF)
* Open Phase (ON)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep brain stimulation of the subthalamic nuclei (STN-DBS)

3 phases :

* Parameter setting
* Cross-over double-bind (ON/OFF)
* Open Phase (ON)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Activa PC Medtronic (7428) stimulator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* severe and resistant Cocaine Dependence for 5 years defined as:

* cocaine dependence (DSM IV),
* preferential use of cocaine in base form (crack or free-base) through smoke,
* non response to at least two well-conducted treatment with at least a stay in aftercare,
* severe physical complications (defined as a history of myocardial infarction, stroke).
* psychotic syndromes induced recurrent, severe lung disease "crack-lungs") occurred due to crack consumption and whose association with the crack use is known to the patient
* age between 30 and 55 years
* patient affiliated to a social security scheme
* patient signed an informed consent after receiving written information on the proposed procedure

Exclusion Criteria

* a current opioid dependence will not be a criterion of non inclusion if the patient is undergoing substitution treatment (methadone or buprenorphine) and not injection of opiates for at least six months.
* patient trust
* pregnant, nursing or of childbearing potential without effective contraception
* current use of the intravenous route for the administration of the drugs is the risk of infection
* VIH infection or VHC unstabilized,
* cardiovascular and / or brain state is not compatible with the surgery,
* other disorder on Axis I not linked to cocaine use except:

* current or past dependence to nicotine,
* abuse or dependence on other psychoactive substances over a lifetime in remission for more than 6 months,
* current opioid dependence: if the patient is undergoing substitution treatment (methadone or buprenorphine) and not injection of opiates for at least 6 months,
* when other psychiatric disorders induced by substances.
Minimum Eligible Age

30 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henri Mondor Hospital

Créteil, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Luc MALLET

Role: CONTACT

(0)1 49 81 30 52 ext. +33

Florence VORSPAN

Role: CONTACT

(0) 1 40 05 44 17 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Philippe DOMENECH

Role: primary

(0) 1 49 81 22 03 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P111014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation (DBS) for Methamphetamine Use Disorder
NCT05558358 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
TDCS for Cocaine Addiction Craving
NCT03833583 COMPLETED NA
D-Serine for Cocaine Dependence Pilot
NCT01715051 WITHDRAWN PHASE2